Insights on the global Genome Editing market to 2027

Company logo

Company logo

Global Genome Editing Market

Global Genome Editing Market

Global Genome Editing Market

Dublin, June 22, 2022 (GLOBE NEWSWIRE) – The “The Genome Editing Market – Forecasts from 2022 to 2027” Report added to ResearchAndMarkets.com Show.

Genome editing is a method for making changes to an organism’s DNA and is used to improve crop yields, diagnose and treat diseases, and for research purposes. Research and development in genome editing is increasing worldwide as it is used in the agriculture and healthcare sectors.

Also, investments in genome editing have increased as the technology is seen to be able to solve many problems, which is expected to drive further market growth during the forecast period.

Moreover, the support of various governments around the world to use genome editing to improve crop yield is another notable factor that is expected to drive the genome editing market. Moreover, the increasing cases of cancer and other genetic disorders increase the need for effective treatment and thus lead to the growth of the market for genome editing.

The COVID-19 pandemic has had a positive impact on the market as researchers have developed new diagnostic tools based on CRISPR, a genome-editing technology, to diagnose COVID-19 patients. This has had a positive impact on the genome editing market and increased the expected growth rates of the genome editing market in 2020 and 2021. As the spread of the Corona virus continues to affect the world with its new waves and variants, the epidemic is expected to spread. Positive impact on the genome editing market in the coming years as well.

Increased incidence of cancer and other genetic disorders

Cases of cancer and other genetic disorders are increasing globally. The growing interest in genome editing for the treatment of cancer and several genetic disorders is expected to drive the growth of the genome editing market during the forecast period.

Recently, in January 2021, NIH researchers discovered a new genetic disorder called deubiquitylation syndrome, which causes developmental delays and impairs the proper formation of the heart, facial features, and brain. . These definitions of new genetic disorders also contribute to the high incidence of genetic disorders. Moreover, cases of cancer are spreading.

According to data from the International Agency for Research on Cancer (IARC), the number of cancer cases in the United Kingdom (England and Wales) increased from 138,577 in 2010 to 156,444 in 2017 for males and from 130,674 in 2010 to 149,239 in 2017 for women.

According to the International Agency for Research on Cancer, the number of cancer cases in Europe is expected to jump from 4.398 million in 2020 to 5.323 million in 2040, an increase of about 21%. In North America, cancer cases are expected to reach 3.525 million in 2040, up from 2.557 million in 2020, a growth rate of nearly 38%. This is expected to have a positive impact on the genome editing market in the coming years, due to the growing need for better cancer treatments.

Increase investment and research in genome editing

In September 2021, the UK government announced its plans to support gene editing in agriculture to support the country’s farmers in growing better and more productive crops. The government is facilitating research and development. It also aims to take the necessary measures to bring genome-modified products to market safely and responsibly.

Moreover, the Government of China supports the use of CRISPR, a genome-editing technology, to improve the country’s food supply.

North America dominates the global market

Geographically, the North American region is expected to hold a significant market share due to the significant investments being made in the region in the field of genome editing. The Asia Pacific region is expected to experience significant growth due to rising cases of genetic disorders and cancer, along with increased spending on healthcare and research. According to IARC data, the number of cancer cases in Asia is expected to increase by more than 59%. Moreover, the use of CRISPR technology is increasing exponentially in China and is expected to contribute more to the market growth in the Asia Pacific region.

Main topics covered:

1 Introduction

2. Research Methodology

3. Executive Summary

4. Market dynamics
4.1 Market Drivers
4.2 Market Restrictions
4.3 Porter’s Five Forces Analysis
4.3.1. Bargaining power of end users
4.3.2. Bargaining power of buyers
4.3.3. Threat of newcomers
4.3.4. The threat of alternatives
4.3.5. Industry competitiveness
4.4 Industry value chain analysis

5. Genome Editing Market Analysis, By Technology
5.1 Introduction
5.2 CRISPR
5.3 Tallinn
5.4. ZFN
5.5 AHR

6. Genome Editing Market Analysis, By Application
6.1 Introduction
6.2 Cell line engineering
6.3 Animal Genetic Engineering
6.4 Plant genetic engineering

7. Genome editing market analysis, by end user
7.1 Introduction
7.2 Academic and government research institutes
7.3. Biotechnology and pharmaceutical companies
7.4. contract research organizations

8. Genome editing and market analysis by geography
8.1 Introduction
8.2 North America
8.2.1. United States of America
8.2.2. Canada
8.2.3. Mexico
8.3 South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Aharon
8.4 Europe
8.4.1. Germany
8.4.2. France
8.4.3. United kingdom
8.4.4. Aharon
8.5 Middle East and Africa
8.5.1. Kingdom Saudi Arabia
8.5.2. The United Arab Emirates
8.5.3. Aharon
8.6 Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Aharon

9. Competitive environment and analysis
9.1 Key players and strategy analysis
9.2. Emerging players and winning the market
9.3 Mergers and acquisitions, agreements and cooperation
9.4 Vendor Competitive Matrix

10. Company Profiles
10.1. Thermo Fisher Scientific Inc.
10.2. Merck & Co., Inc.
10.3. Horizon Discovery Collection plc
10.4. Jane Script
10.5. Sangamo Therapeutics, Inc.
10.6. Integrated DNA Technologies, Inc.
10.7. Lonza Group Ltd.
10.8. BEX Co., Ltd.
10.9. OriGene Technologies, Inc.
10.10. Biopharmaceutical Transposagen, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/y26euv

Attached

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900